Schizophrenia and Substance Use Disorders: Dual-Diagnosis Care
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Schizophrenia and a substance use disorder can occur in the same person, and both conditions deserve assessment and treatment. Dual-diagnosis care brings mental health care, substance use treatment, physical health care, and practical recovery support into a coordinated plan. The core clinical answer is to treat both conditions together, adapt the sequence to immediate needs, and keep care accessible even when symptoms or substance use fluctuate. The National Institute of Mental Health and NICE guidance on coexisting psychosis and substance misuse both describe integrated, person-centered approaches.
This guide explains the clinical distinctions, assessment process, treatment options, research evidence, safety questions, and practical routes to care. It is designed for people living with schizophrenia, family members, caregivers, and professionals. A person's symptoms and substance history require individual clinical evaluation: neither an isolated hallucination nor substance use alone establishes schizophrenia or a substance use disorder.
What Does Dual Diagnosis Mean in Schizophrenia?
Dual diagnosis is a commonly used service term for the co-occurrence of a mental disorder and a substance use disorder (SUD). In this context, it means that a person meets the criteria for schizophrenia and also has a clinically significant pattern of alcohol, cannabis, opioid, stimulant, tobacco, or other substance use that meets diagnostic criteria for an SUD. The phrase is a useful shorthand for planning care; it is not a separate diagnosis in DSM-5-TR or ICD-11.
Schizophrenia is a psychiatric disorder that may include delusions, hallucinations, disorganized thinking or behavior, negative symptoms, and cognitive and functional difficulties. Psychosis refers to a constellation of symptoms or a clinical syndrome and can occur in schizophrenia as well as mood disorders, delirium, substance-related states, and medical or neurological conditions. A substance use disorder is diagnosed from a problematic pattern of use and its consequences, such as impaired control, continued use despite harm, and other substance-specific criteria. The presence of one condition does not prove the other. See the NIMH schizophrenia overview and the NIMH guide to co-occurring disorders.
The word comorbidity describes coexisting conditions. It does not settle which condition developed first, whether one caused the other, or which treatment should begin first. The actual clinical picture may include several substances, depression or anxiety, trauma exposure, chronic pain, housing instability, and physical illness. Good dual-diagnosis care assesses all of these without treating the person as a collection of labels.
Schizophrenia, Substance-Induced Psychosis, and Intoxication: The Critical Distinction
A person who experiences paranoia or voices after using a substance may have acute intoxication effects, a substance- or medication-induced psychotic disorder, an exacerbation of an established schizophrenia-spectrum disorder, or an unrelated psychiatric or medical problem. These possibilities often overlap in their visible symptoms. The distinction matters because clinicians must address acute toxicity or withdrawal as well as any ongoing psychotic disorder.
Substance-induced psychosis
Substance-induced psychosis involves clinically significant psychotic symptoms that develop in a temporal relationship to a substance or medication exposure and are not better explained by another psychotic disorder. Symptoms may resolve after intoxication or withdrawal has passed, but some presentations persist or recur, and some individuals subsequently receive a diagnosis of a primary psychotic disorder. A drug screen by itself does not determine causation. Clinicians review substance timing, dose, other exposures, previous symptom episodes, family and developmental history, and symptom course during periods without use. These distinctions are addressed in NICE CG120 and the NIMH psychosis guide.
Established schizophrenia with co-occurring substance use
When schizophrenia was present before problematic substance use, or psychotic and negative symptoms continue outside periods of intoxication or withdrawal, substance use may still worsen psychosis, sleep, anxiety, medication adherence, and functioning. The clinical team treats the confirmed schizophrenia while assessing and addressing substance use on its own terms. Some people have a substance use disorder without recent use; others use a substance without meeting the criteria for a disorder. Those distinctions shape treatment goals and documentation.
Other conditions that can resemble or accompany psychosis
Bipolar disorder with psychotic symptoms, major depressive disorder with psychotic features, delirium, neurological disorders, neurocognitive disorders, medication adverse effects, and medical illness may all enter the differential diagnosis. Fluctuating attention, altered consciousness, fever, seizures, severe dehydration, or rapidly changing physical signs increase concern for an acute medical process. A symptom checklist, positive urine test, or online quiz cannot replace a qualified longitudinal diagnostic assessment.
How Common Is Substance Use Disorder in Schizophrenia?
Co-occurring substance use disorders are common in schizophrenia, but estimates vary with country, clinical setting, age, substance, diagnostic methods, and whether studies count lifetime or current diagnoses. A 2026 JAMA Psychiatry systematic review and meta-analysis described an approximate co-occurrence rate of 41.7% in the literature it reviewed. That pooled contextual figure is not an individual probability, a universal prevalence rate, or evidence that every person with schizophrenia uses substances.
Tobacco use and nicotine dependence deserve specific attention alongside alcohol, cannabis, stimulants, and opioids. Rates and clinical consequences differ between them, so asking only whether someone uses 'drugs' misses relevant information. Substance use can involve prescribed medicines taken outside their intended use, combinations of substances, and changes in patterns over time. Treatment needs to distinguish use, hazardous use, dependence, withdrawal, and a confirmed SUD rather than equating them.
Why Can These Conditions Occur Together?
Several pathways can contribute to co-occurrence. Shared genetic and environmental vulnerabilities may increase risk for both disorders. Social adversity, disrupted sleep, trauma, isolation, limited housing, and difficulty accessing care may complicate both. Some people report using substances to manage distressing feelings, sleep problems, boredom, or unwanted medication effects; others experience substance-related deterioration in sleep, perception, cognition, or emotional regulation. The NIMH overview of co-occurring disorders describes these bidirectional relationships.
A popular account sometimes suggests that everyone with schizophrenia uses substances to 'self-medicate.' That interpretation is too narrow to explain a heterogeneous population. Motives vary and may include pleasure, social participation, habit, withdrawal avoidance, pain, dependence, and attempts to cope. A clinically useful formulation asks what function the substance serves for this particular person, when use increases, and which environmental conditions make healthier alternatives more accessible.
Substances may also interfere with treatment through intoxication, withdrawal, interactions, impaired attention, missed appointments, or competing priorities. Equally, difficulties accessing mental health care may undermine substance treatment. The relationship is dynamic: a period of reduced substance use may improve sleep and stability, but it does not automatically remove the need for schizophrenia care.
Substances That Require Particular Clinical Attention
Cannabis and high-THC products
Cannabis exposure, especially frequent use and high-potency THC products, is associated with increased risk of psychotic experiences and psychotic disorders in population research. For people already vulnerable to psychosis or living with schizophrenia, cannabis use may be associated with symptom exacerbation and relapse. Association does not establish that cannabis alone caused a specific person's schizophrenia; family history, prior symptoms, potency, frequency, age of exposure, and other factors matter. Clinicians should ask about smoked cannabis, concentrates, edibles, synthetic cannabinoids, and changing product strength. See the WHO schizophrenia fact sheet and NIMH understanding psychosis.
Alcohol and alcohol withdrawal
Alcohol can worsen sleep, depressive symptoms, judgment, adherence, falls, and medication-related sedation. Severe alcohol withdrawal can involve seizures, hallucinations, and delirium and may become life-threatening. A person who is physically dependent on alcohol should discuss medically supervised withdrawal with a qualified clinician rather than abruptly attempting an unsupervised detoxification. The care plan must distinguish alcohol-related hallucinations or delirium from a separate schizophrenia-spectrum disorder. NICE CG120 includes referral and management considerations for severe dependence.
Stimulants, including cocaine and methamphetamine
Stimulants can cause or intensify suspiciousness, insomnia, agitation, and psychotic symptoms; acute stimulant-associated psychosis can be difficult to distinguish from primary psychosis during a crisis. Cardiovascular symptoms, overheating, severe agitation, and prolonged sleep deprivation increase the urgency of medical assessment. A history of stimulant use still does not settle the diagnosis of schizophrenia. Follow-up through a period of stabilization is often needed.
Opioids, sedatives, and polysubstance use
Opioid use disorder raises overdose risk, especially when opioids are combined with alcohol, benzodiazepines, or other sedating drugs. Withdrawal may cause substantial distress and destabilize care. Evidence-based opioid use disorder medications should remain available to eligible people with schizophrenia; the prescribing team must evaluate interactions, sedation, and the complete medication list. People using more than one substance need a coordinated safety plan that addresses combined effects and practical access to overdose prevention. See NIMH on integrated treatment.
Tobacco smoking and nicotine dependence
Tobacco is often overlooked because smoking is legal and common in some clinical settings. It carries major cardiovascular, pulmonary, and cancer risks. There is also a critical medication issue: chemicals in combusted tobacco smoke induce the CYP1A2 metabolic pathway, affecting blood concentrations of medicines including clozapine and olanzapine. Starting or stopping smoking can change exposure to these medicines, so the prescribing clinician may need to monitor symptoms, adverse effects, and drug levels and adjust treatment. Nicotine replacement or vaping does not reproduce the same smoke-combustion enzyme induction. Notify the prescriber before or promptly after a substantial smoking change. See NICE CG178.
How Clinicians Assess a Possible Dual Diagnosis
Assessment starts with collaborative history and a clear description of what has been happening, not a demand for proof of abstinence. Clinicians assess psychotic symptoms and their duration, mood episodes, cognitive changes, sleep, negative symptoms, functioning, suicidal thoughts, and acute medical concerns. They also ask about each substance used, product and route, amount, frequency, recent changes, withdrawal, overdoses, and any use of prescribed medications outside instructions. Where appropriate, they seek the person's consent to involve a family member or another trusted informant.
A useful timeline records the first changes in thinking or behavior, earlier periods of stability, the first psychotic episode, substance initiation and escalation, periods of reduced use, hospitalizations, and responses to prior treatments. This longitudinal approach helps avoid premature attribution to either schizophrenia or substances. Physical examination, vital signs, targeted laboratory tests, medication review, or toxicology testing may be appropriate according to the presentation. Such investigations answer particular safety and diagnostic questions; a positive test is evidence of recent exposure within its detection limits and is not proof that the substance caused psychosis or that an SUD is present. NICE CG120 describes comprehensive joint assessment.
Clinicians should also assess housing security, food access, ability to attend appointments, physical health, trauma and safeguarding needs, cognitive demands, social support, and the person's own goals. Diagnostic uncertainty can be documented and reviewed over time while clinically indicated support begins. A screening instrument identifies concerns for further evaluation; only a qualified assessment can establish a diagnosis.
When Immediate Medical or Psychiatric Help Is Needed
Seek emergency medical assessment if there is suspected overdose, slowed or absent breathing, seizures, severe intoxication, severe alcohol or sedative withdrawal, fever with confusion, sudden changes in consciousness or attention, severe dehydration, chest pain, or an inability to stay safe. Urgent psychiatric evaluation is also warranted for rapidly escalating psychosis, suicidal intent, credible threats of serious harm, or severe immobility, rigidity, or unusual motor symptoms suggestive of catatonia. Medical emergencies can coexist with an established psychiatric diagnosis.
In the United States, call 911 for immediate life-threatening danger. For suicidal crises or emotional distress, call or text 988; for finding treatment services, use SAMHSA's FindTreatment.gov. A supportive response keeps communication calm, reduces stimulation, avoids confrontations about beliefs during an acute episode, and communicates observable safety concerns to clinicians. The goal is prompt assessment and protection, rather than debating whether a symptom was caused by a substance.
What Is Integrated Dual-Diagnosis Care?
Integrated dual-diagnosis care means that schizophrenia treatment and substance use treatment are planned and coordinated as parts of one clinical picture. The model may be delivered by a multidisciplinary team or by connected providers who share an agreed plan with the person's permission. It includes decisions about psychiatric medication, substance-specific medication when indicated, psychological treatment, medical monitoring, crisis planning, housing and social support, and follow-up after setbacks. The key access principle is that people should receive needed mental health care even when they continue to use substances, and substance treatment should remain available when psychotic symptoms are present. NICE CG120, NICE NG58, and NIMH emphasize this coordination.
Integrated, parallel, and sequential treatment
In a sequential model, one service may require the person to complete addiction treatment before psychiatric treatment, or the reverse. This can create delays and gaps when each condition impairs the person's ability to complete the other program. Parallel care offers two simultaneous but relatively separate programs; it can work better when communication and responsibilities are explicit. Integrated care attempts to resolve conflicting advice, duplicated assessments, medication concerns, and transitions through deliberate coordination. The term describes an organization of care, not proof that a particular branded therapy is superior in every randomized trial.
What a shared care plan should contain
A practical plan names who coordinates care; which psychotic symptoms and substance-use patterns are current priorities; medication prescriptions and interactions; how intoxication, withdrawal, overdose, suicide risk, and acute medical illness will be handled; psychotherapy and recovery supports; preferred family involvement; follow-up intervals; and measurable goals defined with the person. Goals may include fewer crises, safer use, reduced consumption, abstinence when appropriate and chosen, improved sleep, medication tolerability, secure housing, returning to work or school, and stronger relationships. NICE CG120 advises adjusting sequence to relative severity, context, and readiness for change.
Antipsychotic Medication When Substance Use Disorder Is Also Present
Antipsychotic medication can be part of evidence-based schizophrenia treatment, with selection based on prior response, expected benefits, adverse effects, physical health, preferences, and practical follow-up. Clinicians consider metabolic risks, movement symptoms, sedation, cardiovascular effects, prolactin effects, and individual interactions. Substance use adds considerations about intoxication, dehydration, missed doses, smoking changes, and medications used for addiction treatment. A dual diagnosis does not establish that one antipsychotic is universally superior to the others: NICE CG120 explicitly advises following schizophrenia prescribing guidance because comparative benefit for a specific antipsychotic in this subgroup has not been established.
Medication should be prescribed and monitored by an appropriate clinician. Abruptly stopping antipsychotic treatment without a plan may increase risk of symptom recurrence. People should have opportunities to discuss side effects, previous treatment experiences, practical barriers, and decisions about dose and delivery method. An antipsychotic's ability to reduce psychotic symptoms is not equivalent to treating the underlying addiction.
Long-acting injectable antipsychotics
Long-acting injectable antipsychotics can be considered when a person prefers this delivery method or when difficulties with regular oral dosing jeopardize schizophrenia treatment. They still require consent, monitoring, and evaluation of risks and benefits. They are treatments for psychotic illness, not specific treatments for substance use disorders, as noted in NICE CG120. They should never be presented as a punishment for ongoing substance use.
Clozapine and treatment-resistant schizophrenia
Clozapine has an established role in treatment-resistant schizophrenia under specialist supervision, after appropriate adequate antipsychotic trials. It requires structured blood monitoring and attention to constipation, cardiovascular complications, sedation, infection symptoms, drug interactions, and smoking changes. Observational research has reported associations between clozapine treatment and better substance-use outcomes in some groups, but this does not make clozapine an approved stand-alone addiction medication or establish its superiority for every dual-diagnosis patient. Its use depends primarily on the patient's schizophrenia indications, risk profile, and specialist assessment. See NICE CG178.
Treating the Substance Use Disorder as a Distinct Clinical Condition
The substance use component deserves its own evidence-based treatment, adapted to the particular substance and the person's clinical situation. For opioid use disorder, clinicians may consider medications such as buprenorphine or methadone; for alcohol use disorder, medicines such as naltrexone or acamprosate may be options in appropriately selected patients. Availability, contraindications, liver or kidney status, opioid exposure, interactions, and goals must be reviewed by qualified prescribers. Treatment should not be withheld solely because schizophrenia is present. NIMH guidance on co-occurring disorders identifies medications for opioid and alcohol addiction as established options.
There is no one medication that reliably treats every type of substance use disorder. Approaches used for tobacco, stimulant, cannabis, alcohol, and opioid problems vary substantially. Some substance-specific behavioral interventions have supportive evidence in their broader populations, but results from trials conducted without schizophrenia cannot be assumed to transfer unchanged to people with active psychosis, negative symptoms, cognitive difficulties, or high service needs. The prescriber and care coordinator should review the full regimen together.
Psychological and Psychosocial Treatment Options
Motivational interviewing and collaborative goals
Motivational interviewing uses a respectful, collaborative conversation about the person's own reasons for change and difficulties with it. It may help identify ambivalence, reduce confrontation, and formulate achievable goals. It is often combined with psychiatric management and other addiction services. A person can receive care before being ready to commit to complete abstinence; readiness is a factor for tailoring the approach, not a reason to abandon treatment. Evidence for added substance-use reduction specifically in schizophrenia remains mixed, so this should be described as a clinical option rather than a guaranteed outcome.
Cognitive behavioral approaches
CBT adapted for psychosis can help a person examine distress, interpretations of experiences, coping responses, avoidance, and daily routines. Addiction-focused CBT may work on cravings, triggers, functional analysis of use, problem-solving, and relapse prevention. When both are present, therapists can adjust pace, memory demands, session structure, and homework to the person's cognitive abilities and current symptoms. These approaches can coexist with medication and practical care. NICE CG178 describes psychosocial treatment for schizophrenia; trial evidence for specifically reducing co-occurring substance use is reviewed below.
Contingency management and behavioral support
Contingency management uses clearly defined, ethically administered rewards tied to specified treatment-related behaviors or substance-use outcomes. It is a recognized approach in substance treatment and may be relevant to some people with psychosis. Its design should preserve autonomy, avoid punitive consequences for missed targets, and use meaningful support. NICE CG120 says a psychosis diagnosis alone should not exclude someone from contingency management. The strength of evidence differs by substance and intervention and needs to be interpreted for this clinical population.
Family psychoeducation and supportive relationships
Family and trusted supporters can learn to recognize changes in sleep, functioning, psychosis, or substance use; support appointments and medication discussions; reduce escalating conflict; and develop agreed crisis contacts. With the person's permission, shared information can prevent contradictory plans between providers and loved ones. Confidentiality, autonomy, and adult consent remain central. Families also need care for their own stress and can benefit from education and peer support. See the NIMH schizophrenia publication.
Case management, housing, work, and education
Housing instability, transportation barriers, poverty, and interrupted insurance can undermine both treatments even when a medication or therapy is appropriate. Case management, assertive community treatment for selected high-need individuals, supported employment and education, occupational support, and connection to primary care can address everyday barriers. Early intervention programs may combine these services around a first episode of psychosis. Improving participation and safety is part of recovery, even when substance-use outcomes change gradually. NIMH describes coordinated specialty care and community treatment.
What Do Systematic Reviews Actually Show?
Service recommendations for coordinated, accessible treatment and proof of superiority for a specific psychological intervention answer different questions. Three important evidence syntheses show why a responsible article needs both a clinical care framework and careful claims about effectiveness.
The 2026 JAMA Psychiatry meta-analysis
Salahuddin and colleagues' 2026 systematic review included 35 randomized trials with 4,136 participants, of which 29 trials and 3,831 participants contributed to pairwise analyses. Compared with control conditions, psychological and psychosocial interventions showed a very small estimate favoring intervention for overall psychiatric symptoms, but the confidence interval included no effect (standardized mean difference −0.11; 95% confidence interval −0.27 to 0.05; low confidence). Across the analyzed substance-use outcomes, the pooled estimate was essentially null (SMD −0.01; 95% confidence interval −0.21 to 0.18; moderate confidence), with a small positive signal for nicotine outcomes. The findings point to limitations in the interventions tested and the need for better research; they do not justify excluding people from treatment or denying other established schizophrenia and SUD care.
The 2024 Schizophrenia Bulletin review
Siddiqui and colleagues' 2024 systematic review synthesized 35 randomized trials with 5,176 participants across comorbid psychotic disorders and substance use, including approximately 2,840 people with schizophrenia-spectrum disorders. Its pooled estimate for substance-use outcomes was not statistically significant (SMD −0.05, 95% CI −0.16 to 0.07), and overall certainty was low. The sample was clinically heterogeneous, and interventions differed in content, intensity, comparison conditions, and follow-up.
The 2019 Cochrane review
Hunt and colleagues' Cochrane review included 41 studies and 4,024 people with severe mental illness and substance misuse. It found insufficient high-quality evidence to favor one psychosocial intervention over standard care for major outcomes, while underscoring methodological limitations, attrition, and differing interventions. Because the population extended beyond schizophrenia, the estimates should not be presented as exclusively schizophrenia-specific.
These reviews test particular interventions against particular comparators. A service model that avoids exclusion, coordinates medication and risk management, and helps people attend treatment also responds to practical and ethical access needs that a pooled substance-use score may not fully capture. The defensible conclusion is to provide evidence-based care for both diagnoses, measure actual patient-centered outcomes, remain transparent about mixed incremental trial results, and improve interventions through research.
Early Psychosis, Adolescents, and First-Episode Care
When psychosis first appears during adolescence or young adulthood, clinicians need to distinguish the effects of substances from an emerging psychotic disorder without postponing medical or mental health assessment. The first episode may be frightening and confusing, and patients and families often need help understanding what is known, what remains uncertain, and what follow-up will clarify. Coordinated specialty care for early psychosis may include medication decisions, psychotherapy, family work, case management, and supported school or work participation. The NIMH guide to psychosis and its schizophrenia publication explain early intervention.
Clinical high risk for psychosis, or attenuated psychotic symptoms, describes specialist assessment states with predictive limits, not a confirmed schizophrenia diagnosis. Screening results and cannabis exposure do not justify telling a young person that schizophrenia is inevitable. For minors, assessment and safeguarding should be age-appropriate, with attention to consent, family context, development, and transitions between pediatric and adult services. NICE CG155 provides guidance for psychosis in children and young people.
Harm Reduction, Relapse Planning, and Long-Term Recovery
Recovery planning should accommodate changes over time. A person may achieve abstinence, reduce use, engage in safer practices, or need repeated support after a return to substance use. A return to use calls for renewed assessment of overdose risk, withdrawal, psychiatric symptoms, and barriers to care; it is not proof that treatment has failed permanently. Safety measures can include naloxone access when opioids are involved, not mixing sedating substances, prompt recognition of withdrawal risk, secure medication management, and agreed routes to urgent care. Specific recommendations belong to trained providers who know the person's substances and circumstances.
For psychosis, a personalized relapse plan might identify early changes in sleep, suspiciousness, withdrawal from usual activities, difficulty organizing thoughts, or return of distressing voices; it also names whom to contact and what kind of assistance has helped before. Avoid interpreting every change as relapse: physical illness, sleep deprivation, intoxication, withdrawal, and medication adverse effects can also require evaluation. Regular medication review and physical health monitoring matter over years. Recovery can include improved safety, stable relationships, meaningful activities, personal goals, and self-determination, with or without ongoing symptoms.
Physical Health, Medication Safety, and Social Inequities
People with schizophrenia may face disproportionate physical-health burdens, including cardiometabolic risk associated with illness, social determinants, tobacco use, and some psychiatric treatments. Alcohol, illicit substances, injection-related risks, and barriers to preventive care can add further harm. Primary care and psychiatric services should coordinate blood pressure, weight, blood glucose or A1c, lipids, smoking cessation support, infectious disease screening where appropriate, and medication-specific monitoring. WHO, NICE CG178, and the VA/DoD schizophrenia guideline provide clinical context.
Stigma can operate twice: people may encounter prejudice associated with psychosis and judgment associated with addiction. Service exclusion, fragmented reimbursement, criminalization, unstable housing, and transportation barriers create tangible obstacles. Respectful language and practical accommodation are part of safe care. Clinicians should ask what care arrangement the individual can actually access, especially when cognitive symptoms, financial stress, or fluctuating capacity make complex referrals difficult.
How Family Members and Supporters Can Help
Supporters can ask how the person describes their own needs, offer assistance arranging an integrated assessment, help track a timeline of symptoms and exposures if invited, and reduce barriers to appointments, transportation, or medication refills. During a distressing experience, focus on safety and the emotion the person is experiencing rather than forcefully arguing about delusions. Make concrete offers such as accompanying someone to an appointment or helping them record questions for the care team.
Collaborative boundaries are equally important. Supporters can communicate concerns without humiliating the person, negotiate what information is shared, avoid supplying intoxicating substances, and make their own safety plan when necessary. If intoxication, withdrawal, overdose, or psychosis creates an emergency, obtain urgent assistance. Families can ask for psychoeducation, crisis planning, and support for caregiver burden. Adult confidentiality rules should be respected; providers can often listen to collateral safety information even when they cannot disclose protected clinical details.
Questions to Ask a Dual-Diagnosis Treatment Team
Useful questions include: What evidence supports the current diagnoses, and which possibilities still need follow-up? Who is coordinating schizophrenia and substance use treatment? What should happen if intoxication, withdrawal, or psychosis becomes acute? Are the current medications compatible, and what monitoring is needed if smoking changes? Which treatments address the specific substance involved? What options exist if an intervention is ineffective or difficult to attend? How will housing, transportation, work, and family involvement be addressed? How will our goals and progress be reviewed?
A clear response should identify a named contact, immediate safety instructions, a method for sharing information between services with consent, and next steps for routine follow-up. People can request explanations in accessible language, supported decision-making, and reevaluation when symptoms or circumstances change.
Frequently Asked Questions
Can drugs or alcohol cause schizophrenia?
Certain exposures, especially cannabis in the context of other vulnerabilities, are associated with an increased risk of psychotic disorders, while intoxication and withdrawal can produce psychotic symptoms themselves. Whether a substance caused a particular person's disorder cannot be established from exposure history alone. Clinicians consider longitudinal symptoms, diagnostic criteria, competing explanations, and medical findings.
Is substance-induced psychosis the same as schizophrenia?
No. Substance-induced psychosis is diagnosed in relation to substance or medication exposure and its clinical course. Schizophrenia is a primary psychiatric disorder identified through a broader diagnostic and longitudinal assessment. Similar symptoms may be present in both, and diagnostic reassessment after stabilization may be essential.
Must someone stop all substance use before receiving treatment for schizophrenia?
No. NICE guidance and NIMH recommend that the presence of substance use should not become a blanket reason to deny needed mental health care. Acute intoxication or withdrawal may require immediate medical stabilization, while longer-term psychiatric and substance-use care remains coordinated.
Does an antipsychotic cure addiction?
Antipsychotics treat aspects of schizophrenia and other indicated conditions. They are not substitutes for substance-specific assessment and evidence-based addiction treatment. Medication selection also requires attention to sedation, interactions, physical health, and monitoring. Claims that a particular antipsychotic treats addiction better than others are not established for all patients with psychosis and co-occurring substance misuse.
Can a person take medication for opioid or alcohol use disorder while receiving schizophrenia treatment?
Often, yes, when clinically appropriate. Qualified prescribers should assess indications, interactions, safety, medical comorbidities, and follow-up, and coordinate the treatment plan. A schizophrenia diagnosis alone is not a reason to deny proven substance-specific care.
Why does stopping smoking matter for clozapine?
Combusted tobacco smoke affects the metabolism of clozapine and certain other medicines. A major reduction in or resumption of smoking can change medicine levels and adverse effects. The psychiatrist or prescribing clinician should be informed so they can monitor and adjust treatment as needed. This interaction relates mainly to smoke combustion, rather than nicotine itself.
What if the person rejects addiction treatment or is unsure about changing substance use?
Care can begin with immediate concerns, respectful engagement, safety, a discussion of personally important goals, and treatment for schizophrenia. Clinicians can use collaborative motivational strategies and revisit goals over time. Continuing psychiatric care and keeping the door open to substance treatment can be more useful than an all-or-nothing requirement.
Can someone recover while living with both diagnoses?
Yes. Meaningful improvement in symptoms, substance use, health, relationships, housing, education, employment, or quality of life is possible. Outcomes vary widely. Some people need sustained specialist support, while others achieve periods of high functioning with individualized care. Neither diagnosis predetermines a person's future.
Where can someone in the United States find integrated treatment?
A primary care clinician, psychiatrist, community mental health center, early psychosis program, or addiction specialist can help coordinate evaluation. FindTreatment.gov is a federal treatment locator. Ask prospective programs directly whether they treat both schizophrenia-spectrum disorders and the relevant SUD and whether they coordinate medication, crisis services, and follow-up. For a life-threatening emergency, call 911; for a mental health or suicide crisis, call or text 988.
The Clinical Bottom Line
Co-occurring schizophrenia and substance use disorders call for two sound diagnostic evaluations, timely responses to acute risks, and treatment that remains coordinated across psychiatry, addiction medicine, physical health, and social support. Specific evidence-based treatments are chosen for each condition, while the care plan accounts for their interactions. The strongest practical standard is an accessible, individualized, respectful treatment pathway with shared decisions and continuing reassessment. The evidence for particular added psychosocial interventions in this subgroup is mixed, and transparent outcome monitoring is part of good care.
For the broader clinical context, see Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery.
Related Articles
References
Hunt, G. E., Siegfried, N., Morley, K., Brooke-Sumner, C., & Cleary, M. (2019). Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews, CD001088. https://doi.org/10.1002/14651858.CD001088.pub4
National Institute for Health and Care Excellence. (2011; current guidance). Coexisting severe mental illness (psychosis) and substance misuse: Assessment and management in healthcare settings (CG120). https://www.nice.org.uk/guidance/cg120
National Institute for Health and Care Excellence. (2013; current guidance). Psychosis and schizophrenia in children and young people: Recognition and management (CG155). https://www.nice.org.uk/guidance/cg155
National Institute for Health and Care Excellence. (2014; current guidance). Psychosis and schizophrenia in adults: Prevention and management (CG178). https://www.nice.org.uk/guidance/cg178
National Institute for Health and Care Excellence. (2016). Coexisting severe mental illness and substance misuse: Community health and social care services (NG58). https://www.nice.org.uk/guidance/ng58
National Institute of Mental Health. (2025). Finding help for co-occurring substance use and mental disorders. https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health
National Institute of Mental Health. (n.d.). Schizophrenia. https://www.nimh.nih.gov/health/publications/schizophrenia
National Institute of Mental Health. (n.d.). Understanding psychosis. https://www.nimh.nih.gov/health/publications/understanding-psychosis
Salahuddin, N. H., Herlitzius, E., Schütz, A., et al. (2026). Psychological and psychosocial interventions for people with schizophrenia and co-occurring substance use disorders: A systematic review and meta-analysis. JAMA Psychiatry, 83(4), 353–362. https://doi.org/10.1001/jamapsychiatry.2025.4390
Siddiqui, S., Mehta, D., Coles, A., et al. (2024). Psychosocial interventions for individuals with comorbid psychosis and substance use disorders: Systematic review and meta-analysis of randomized studies. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbae101
Substance Abuse and Mental Health Services Administration. (n.d.). FindTreatment.gov: National treatment referral resource. https://findtreatment.gov/
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of first-episode psychosis and schizophrenia. https://www.healthquality.va.gov/guidelines/mh/scz/index.asp
World Health Organization. (2026, September 11). Schizophrenia. https://www.who.int/en/news-room/fact-sheets/detail/schizophrenia